Showing 11 posts of 11 posts found.


NHS guidelines on prescription cannabis to be challenged in court

August 18, 2020
Manufacturing and Production, Research and Development CBD, cannabis, epilepsy

The cannabis guidelines followed by the NHS are set to be challenged in court by the parents of a three-year-old …


FDA approves CBD treatment for seizures associated with tuberous sclerosis complex

August 3, 2020
Sales and Marketing CBD, tsc

The FDA has approved Epidiolex (cannabidiol) as a treatment for seizures associated with tuberous sclerosis complex (TSC) in patients over …


FDA sets out guidelines on cannabis derived drugs

July 22, 2020
Research and Development CBD, CBD Oil

The FDA has released their guidelines on the rules companies should follow when developing cannabis derived drugs. The guidelines cover …


UK Home office reclassifies Epidyolex as a Schedule 5 drug

June 24, 2020
Research and Development CBD, cannabiodiol, cannabis

The Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a Schedule 5 drug, a move …


NHS to fast track cannabis-based treatment for epilepsy

December 23, 2019
Sales and Marketing CBD, CBD Oil, cannabis, drug treatment, epilepsy, thc

The NHS has fast-tracked the drug Epidyolex, a cannabidiol (CBD), to be available for epilepsy treatment through the NHS in …


British Pharmacists call for regulation on non-medicinal CBD products

December 17, 2019
Manufacturing and Production CBD, CBD Oil, CBD Products, cannabis

Pharmacists are calling for more checks on products containing Cannabis derivative cannabidiol (CBD) that are sold in shops across the …


FDA issues warning to CBD company Curaleaf

July 29, 2019
Sales and Marketing CBD, FDA, cannabidiol, curaleaf, pharma, regulation

The FDA has issued a warning to Massachusetts-based CBD company Curaleaf over the firm’s use of unsubstantiated claims about the …


Synthetic, non-intoxicating CBD analogue treats seizures in rats

May 31, 2019
Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …


GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial

May 7, 2019
Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc

GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …

CBD could be used to deliver drugs into the brain, research shows

April 18, 2019
Research and Development BBB, CBD, CNS, brain, drug delivery, neuroscience

Cannabidiol (CBD), one of 113 cannabinoids in cannabis plants, could be used to deliver medicines into the brain, according to …


CBD dampens activity in brain regions associated with psychosis, study shows

August 30, 2018
Research and Development CBD, King's College London, Kings College London, Marijuana, psychosis, study

Cannabidiol (CBD), one of the major constituents of cannabis, may be beneficial for patients with psychotic disorders due to its …

Latest content